Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +10.00p +0.59% 1,702.00p 1,701.00p 1,702.00p 1,709.00p 1,686.00p 1,687.00p 678,764.00 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 977.3 215.8 85.9 17.0 4,095.49

Hikma Pharmaceuticals Share Discussion Threads

Showing 426 to 450 of 450 messages
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
07/12/2016
21:46
Surly the big director buys are certainly a boast of confidence? These seem overweight IMO ... any other thoughts?
g2theary
07/12/2016
17:33
Who is 8x p/e?... pfizer and lly are both about 30, abbv is at 15... Hikma is still a growing company and deserves a higher pe but 8 seems low even for an established low growth company.Someone is confident that this has more to drop however as the short interest is over 4%
coppertrader
07/12/2016
16:49
Ask yourself why Hikma deserves to trade at 20 x 2017 earnings when the rest of the US sector trades at 8x. Healthy 22% ROCE?
farnesbarnes
05/12/2016
19:25
Currently in 98th place with a share price of 1669... mcap of approx 4004, relegation occurs when companies drop below 110th
coppertrader
05/12/2016
12:56
Another £6M for Darwazah...
g2theary
02/12/2016
19:49
More director buys.. I'd be surprised if this goes much lower now... any points to suggest otherwise?
g2theary
29/11/2016
16:33
I assume these will just about stay in the FTSE100 tomorrow anyone know for sure as I can't find any news regarding HIK on this matter?
g2theary
18/11/2016
20:49
Egypt weakness?
r ball
17/11/2016
21:56
Morgan Stanley
nortic 007
17/11/2016
16:34
rrb who or what is MS please?
ali47fish
17/11/2016
15:31
Ask yourself why Hikma deserves to trade at 20 x 2017 earnings when the rest of the US sector trades at 8x. Read the full MS note and you'll see their analysis is based on lots of very optimistic assumptions.
rrb
16/11/2016
20:37
They say 50% of a gain is given back.
r ball
15/11/2016
15:12
A very bullish note
tsmith2
15/11/2016
13:55
Ftalphaville today's chat.
r ball
15/11/2016
12:51
any details?
tsmith2
15/11/2016
12:47
Sellside note today.
r ball
10/11/2016
22:58
Obamacare repeal..
tsmith2
10/11/2016
12:42
Any broker comments - seems cautious, underpromise statement
tsmith2
10/11/2016
09:57
(ShareCast News) - Hikma Pharmaceuticals said on Thursday that it is currently generating "good" revenue growth and expects revenue for the full year to rise by around 35% to $2bn at constant currency. The injectables division has been performing well in the year to date thanks to investments across its geographies to broaden the company's portfolio and strengthen manufacturing capabilities. Meanwhile, in the US, good demand across a number of products and new product launches have more than offset increased competition for certain products. The group said it remains on course to deliver global injectables revenue growth in the mid to high-single digits this year. In addition, thanks to a favourable product mix, it now expects the core operating margin to be around 39%, up from previous guidance of 38%. Hikma said it has been more challenging than expected since August to generate volume growth in certain products in the generics business. This is expected to continue throughout the rest of the year and the group said full-year revenue in the segment is likely to come in at around $600m. It still sees full-year core operating profit at between $30m and $40m, reflecting cost savings, including the optimisation of research and development expenses. In 2017, the enlarged generics business is expected to generate revenue of around $800m. In the branded division, Hikma has seen a steady improvement in revenue at constant currency in the second half. Due to its focus on higher quality sales and a more challenging environment in the GCC, overall growth has been slightly lower than it was anticipating, however. The company said the full-year results for the segment on a reported basis will be hit by currency headwinds, which have become more challenging since the recent devaluation of the Egyptian pound. On a constant currency basis, branded revenue growth is likely to be in the mid-single digits. Chairman and chief executive Said Darwazah said: "Across the group, we are improving the quality of sales and focusing on profitability. Our global injectables business is delivering good growth and extremely strong margins. In MENA, our focus on strategic products and greater operating efficiencies is helping to absorb strong currency headwinds. In Generics, the integration of the West-Ward Columbus acquisition is progressing well and we are rapidly implementing cost savings. Although revenue from West-Ward Columbus is ramping up more slowly than originally anticipated, we remain highly confident in the future prospects of the business."
gertie2shoes
10/11/2016
07:32
$40mn miss versus t/o of $2bn, so not really much in scheme of things.Also this is in $ and price has been smashed of late, let's see..
tsmith2
10/11/2016
07:11
Generics miss.
r ball
09/11/2016
16:58
Trump and abolishing obamacare.
r ball
09/11/2016
16:39
trading update tomorrow? I'm litre bit surprised these aren't up more on the day given obamacare is now likely to be shelved..Wait and see but could well motor up
tsmith2
09/11/2016
13:40
I bought in today,as im happy to hold for longer time, as bought my average cost down as over 20£ last purchase,
barriew
09/11/2016
12:28
£300 loss :(
sandeep67
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161207 22:13:01